Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Hypoglycemia

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Oral Hypoglycemic Agents: Sulfonylureas

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mismatch Between Sensor and Symptoms: The Complex Reality of Hypoglycemia Around Exercise in Type 1 Diabetes Patients Using AID Systems.

Diabetes, obesity & metabolism·2026

Same author

Economic burden of type 2 diabetes management in France according to clinical characteristics.

Diabetes, obesity & metabolism·2026

Same author

Endoplasmic reticulum-mitochondria contact sites are signalling hubs connecting nutrient sensing and GLP-1 secretion in L cells of the mouse gut: from physiology to obesity and type 2 diabetes.

Diabetologia·2026

Same author

Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA<sub>1c</sub> (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial.

The lancet. Diabetes & endocrinology·2026

Same author

Psychosocial burden in type 1 diabetes: a cross-sectional network analysis in the SFDT1 study.

BMJ open·2026

Same author

Tubeless Insulin Pump Combined with a Cloud-Based Data Management Platform: Real-World Evidence from 14,765 French People with Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2025

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

[New hypoglycemic agents in type 2 diabetes].

Bruno Guerci¹, Charles Halter

¹Université de Nancy I et service de diabétologie, maladies métaboliques et maladies de la nutrition, hôpital Jeanne-d'Arc, CHU de Nancy, 54201 Toul BP 90303. b.guerci@chu-nancy.fr

La Revue Du Praticien

|May 15, 2010

Summary

New type 2 diabetes treatments leverage incretins like GLP-1. Therapies include GLP-1 receptor agonists and DPP-4 inhibitors, offering improved glucose control and potential weight loss, though long-term safety requires further study.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Experiment Videos

Last Updated: Jun 13, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Area of Science:

Endocrinology
Pharmacology
Metabolic Diseases

Background:

Type 2 diabetes involves altered incretin effect, with reduced glucagon-like peptide-1 (GLP-1) concentrations.
GLP-1 plays a crucial role in glucose homeostasis, with glucose-dependent insulin secretion and glucagon regulation.
Existing incretin-based therapies aim to restore the diminished incretin effect in type 2 diabetes patients.

Purpose of the Study:

To review novel therapeutic strategies for type 2 diabetes targeting the incretin system.
To compare the efficacy and side effect profiles of GLP-1 receptor agonists and DPP-4 inhibitors.
To assess the impact of these treatments on glycemic control, weight, and overall patient tolerance.

Main Methods:

Review of current literature on incretin-based therapies for type 2 diabetes.
Comparative analysis of subcutaneous GLP-1 receptor agonists and oral DPP-4 inhibitors.
Evaluation of reported HbA1c reductions, weight changes, and adverse events.

Main Results:

GLP-1 receptor agonists showed HbA1c reductions of 0.8-1.5% and significant weight loss (1.6-3.8 kg) due to reduced gastric emptying and satiety control.
DPP-4 inhibitors demonstrated HbA1c reductions of 0.5-1.1% with generally good tolerance.
GLP-1 receptor agonists were associated with gastrointestinal side effects like nausea and vomiting, particularly upon initiation.

Conclusions:

Both GLP-1 receptor agonists and DPP-4 inhibitors represent effective strategies for managing type 2 diabetes by enhancing the incretin system.
GLP-1 receptor agonists offer additional benefits of weight loss, while DPP-4 inhibitors provide oral administration convenience and better initial tolerance.
Further research is necessary to fully establish the long-term effectiveness and safety profiles of these innovative incretin-based treatments.